Education
About Us
Working with TipRanks
Follow Us
Burning Rock Biotech Ltd. (BNR)
NASDAQ:BNR
RESEARCH TOOLSreports
Top Page
Burning Rock Biotech
(NASDAQ:BNR)
52Neutral
Burning Rock Biotech (BNR) vs. S&P 500 (SPY)
Market Cap
$33.48M
Dividend YieldN/A
Average Volume (3M)12.14K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth-10.56%
EPS Growth41.02%
CountryUS
Employees786
SectorHealthcare
Sector Strength74
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-4.68
Shares Outstanding8,232,740
10 Day Avg. Volume18,650
30 Day Avg. Volume12,141
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.79
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Burning Rock Biotech Business Overview & Revenue Model
Company DescriptionBurning Rock Biotech (BNR) is a biotechnology company focused on the development and application of next-generation sequencing (NGS) technology for precision oncology. The company operates primarily in the healthcare and biotechnology sectors, providing products and services aimed at clinical diagnosis and treatment of cancer. Burning Rock specializes in offering NGS-based cancer therapy selection tests, early cancer detection tests, and research services for pharmaceutical companies.
How the Company Makes MoneyBurning Rock Biotech makes money through several revenue streams, primarily centered around its NGS-based products and services. The company generates revenue by offering diagnostic tests that help in the selection of targeted cancer therapies, which are used by hospitals and healthcare providers. Additionally, Burning Rock provides early cancer detection tests, which are a growing segment of their business. The company also partners with pharmaceutical companies, providing genomic profiling services to support drug development and clinical trials. These partnerships are crucial in expanding their market reach and enhancing their revenue potential. Furthermore, Burning Rock may engage in licensing its technology or intellectual property, contributing another stream to its income.
Burning Rock Biotech Financial Statement Overview
Summary
Burning Rock Biotech faces significant profitability and cash flow challenges, with a declining revenue and continued losses. The company maintains a strong equity position and low leverage, but strategic adjustments are needed for long-term sustainability.Income Statement
Burning Rock Biotech shows declining revenue over the past year with a revenue decrease of 4.93% from the previous period. The gross profit margin improved slightly to 68.72%, but the company remains unprofitable with a negative net profit margin of -83.69%. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.45
Neutral
Balance Sheet
The company has a solid equity base with an equity ratio of 65.82%, but the return on equity is negative at -65.95% due to consistent losses. The debt-to-equity ratio is low at 0.16, indicating low financial leverage. However, the declining total assets signal potential concerns about future growth capacity.55
Neutral
Cash Flow
Cash flow from operations improved in the TTM period, but remains negative. The free cash flow to net income ratio is 0.32, indicating a modest cushion for covering net losses. However, the free cash flow growth rate is negative, reflecting cash flow management challenges.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 510.88M | 537.43M | 563.24M | 507.86M | 429.90M | 381.68M | Gross Profit |
| 351.09M | 363.23M | 380.04M | 364.15M | 313.92M | 273.33M | EBIT |
| -441.96M | -669.32M | -980.41M | -797.06M | -412.40M | -169.09M | EBITDA |
| -390.82M | -517.90M | -856.31M | -746.50M | -373.26M | -136.38M | Net Income Common Stockholders |
| -427.55M | -653.69M | -971.23M | -796.70M | -373.71M | -168.34M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 136.25M | 615.10M | 905.45M | 1.50B | 2.26B | 408.22M | Total Assets |
| 372.67M | 1.04B | 1.59B | 2.28B | 2.66B | 847.56M | Total Debt |
| 269.60M | 12.32M | 50.79M | 86.69M | 46.88M | 67.47M | Net Debt |
| 176.26M | -602.77M | -854.66M | -1.34B | -1.85B | -26.76M | Total Liabilities |
| 380.02M | 271.59M | 429.13M | 433.28M | 242.02M | 1.74B | Stockholders Equity |
| -7.34M | 768.41M | 1.16B | 1.85B | 2.42B | -891.49M |
| Cash Flow | Free Cash Flow | ||||
| -135.45M | -265.17M | -518.84M | -691.33M | -153.08M | -273.77M | Operating Cash Flow |
| -127.34M | -255.78M | -456.81M | -477.89M | -73.54M | -228.04M | Investing Cash Flow |
| -3.93M | -9.30M | -7.46M | 81.70M | -109.31M | -346.66M | Financing Cash Flow |
| -1.91M | -48.83M | -86.24M | -52.90M | 2.17B | 571.74M |
Burning Rock Biotech Technical Analysis
Negative
3.36
Price Trends
5.70
Negative
6.00
Negative
5.45
Negative
Market Momentum
-0.44
Positive
32.06
Neutral
5.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNR, the sentiment is Negative. The current price of 3.36 is below the 20-day moving average (MA) of 4.76, below the 50-day MA of 5.70, and below the 200-day MA of 5.45, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 32.06 is Neutral, neither overbought nor oversold. The STOCH value of 5.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNR.
Burning Rock Biotech Risk Analysis
Burning Rock Biotech disclosed 88 risk factors in its most recent earnings report. Burning Rock Biotech reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Burning Rock Biotech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $20.54B | ― | -19.42% | ― | 56.75% | 59.77% | |
66 Neutral | $8.95B | 111.52 | 2.27% | ― | 0.66% | -75.89% | |
52 Neutral | $33.48M | ― | -51.22% | ― | -10.56% | 41.02% | |
52 Neutral | $8.45B | ― | -37.09% | ― | 10.37% | -389.98% | |
49 Neutral | $12.09B | ― | -30.11% | ― | -2.93% | -4.69% | |
49 Neutral | $5.41B | ― | -4584.47% | ― | 31.04% | 16.91% | |
48 Neutral | $6.36B | 1.28 | -45.04% | 2.64% | 19.24% | 1.69% |
* Healthcare Sector Average
Performance Comparison
BNR
Burning Rock Biotech
3.03
-4.57
-60.13%
EXAS
Exact Sciences
43.74
-29.21
-40.04%
ILMN
Illumina
71.26
-55.76
-43.90%
QGEN
Qiagen
40.05
-1.11
-2.70%
NTRA
Natera
143.28
46.57
48.15%
GH
Guardant Health
41.14
22.46
120.24%
Burning Rock Biotech Earnings Call Summary
Earnings Call Date: Mar 25, 2025 | % Change Since: -38.91% | Next Earnings Date: Jun 3, 2025
Earnings Call Sentiment Positive
The earnings call presented a positive financial turnaround with significant improvements in sales efficiency, profitability, and in-hospital revenue growth. Despite industry challenges, the company demonstrated a strong cash position and strategic adaptability.Highlights
Record Low Sales and Marketing Expenses
Achieved sales and marketing expenses as a percentage of revenue at 35%, marking a historic low and the most efficient quarter in recent operating history.
Positive Financial Turnaround
Turned profitable again in Q1 2024 after challenges in Q3 and Q4 of 2023, with a focus on making the company cash flow positive in the future.
In-Hospital Revenue Growth
First quarter where revenue from in-hospital surpassed Central Lab, with overall revenue up 4% quarter-over-quarter, driven by in-hospital growth.
Strong Cash Position
Ended the quarter with RMB 573 million cash balance and a reduced cash outflow, providing a good 3-year cash runway without the need for capital raising.
Lowlights
Industry Operating Environment Challenges
Faced changes in the industry's operating environment starting July last year, impacting revenue distribution and necessitating a transition strategy.
Company Guidance
During Burning Rock's Q1 2024 earnings call, the company provided optimistic guidance, highlighting significant improvements in their financial metrics. The sales and marketing expenses were reduced to 35% of revenue, marking a historic efficiency level, which underpins their operating profitability. The company's gross profit minus SG&A expenses turned positive again in Q1 2024, after a challenging Q3 and Q4 in 2023. Burning Rock ended the quarter with an RMB 573 million cash balance and projected a cash outflow between RMB 150 million to RMB 200 million for 2024. They also noted a successful transition in their revenue model, with more income now coming from in-hospital services than from Central Labs, contributing to a 4% increase in overall revenue quarter-over-quarter. The company aims to maintain positive non-GAAP gross profit minus SG&A for the entirety of 2024 and anticipates further cash flow improvements into 2025.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.